FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100705 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100706 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sun L, et al. 2021. Cancer Cell. :. PubMed
  2. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  3. Liu J, et al. 2019. Immunity. 50:600. PubMed
  4. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  5. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  6. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  7. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  8. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  9. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  10. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  11. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  12. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  13. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  14. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  15. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  16. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  17. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  18. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  19. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  20. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  21. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  22. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  23. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  24. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  25. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  26. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  27. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  28. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  29. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  30. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  31. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  32. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  33. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  34. Morales D, et al. 2015. J Virol. 89:337. PubMed
  35. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  36. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  37. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  38. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  39. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  40. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  41. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  42. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  43. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  44. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  45. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  46. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  47. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  48. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  49. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  50. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  51. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  52. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  53. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  54. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  55. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  56. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  57. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  58. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  59. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  60. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  61. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  62. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  63. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  64. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  65. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  66. Köchl R, et al. 2020. Elife. 9:00. PubMed
  67. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  68. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  69. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  70. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  71. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  72. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  73. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  74. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  75. Wu J, et al. 2020. Immunity. 53:115. PubMed
  76. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  77. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  78. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  79. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  80. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  81. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  82. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  83. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  84. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  85. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  86. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  87. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  88. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  89. Yang J, et al. 2020. Nature. 586:572. PubMed
  90. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  91. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  92. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  93. Wan X, et al. 2018. Nature. 560:107. PubMed
  94. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  95. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  96. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  97. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  98. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  99. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  100. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  101. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  102. Du J, et al. 2018. AMB Express. 8:158. PubMed
  103. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  104. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  105. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  106. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  107. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  108. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  109. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  110. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  111. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  112. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  113. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  114. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  115. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  116. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  117. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  118. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  119. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  120. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  121. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  122. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  123. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  124. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  125. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  126. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  127. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  128. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  129. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  130. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  131. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  132. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  133. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  134. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  135. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  136. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  137. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  138. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  139. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  140. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  141. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  142. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  143. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  144. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  145. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  146. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  147. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  148. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  149. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  150. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  151. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  152. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  153. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  154. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  155. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  156. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  157. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  158. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  159. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  160. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  161. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  162. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  163. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  164. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  165. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  166. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  167. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  168. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  169. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  170. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  171. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  172. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  173. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  174. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  175. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  176. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  177. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  178. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  179. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  180. Li H, et al. 2022. iScience. 25:104481. PubMed
  181. Wang X, et al. 2022. Elife. 11:. PubMed
  182. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  183. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  184. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  185. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  186. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  187. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  188. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  189. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  190. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  191. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  192. Xie L, et al. 2020. Infect Immun. :88. PubMed
  193. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  194. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
  195. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  196. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  197. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  198. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  199. Lee S, et al. 2021. Autophagy. Online ahead of print. PubMed
  200. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  201. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  202. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  203. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  204. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312745 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC, IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC, CyTOF®, IHC-F, IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC, 3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC, IHC-F, 3D IHC, SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC, IHC, SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC, CyTOF®, IHC, IP, Depletion, Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC, CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F, FC, 3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD8a

  • Biotin anti-mouse CD8a

  • FITC anti-mouse CD8a

  • PE anti-mouse CD8a

  • PE/Cyanine5 anti-mouse CD8a

  • Purified anti-mouse CD8a

  • PE/Cyanine7 anti-mouse CD8a

  • APC/Cyanine7 anti-mouse CD8a

  • Alexa Fluor® 488 anti-mouse CD8a

  • Alexa Fluor® 647 anti-mouse CD8a

  • Pacific Blue™ anti-mouse CD8a

  • Alexa Fluor® 700 anti-mouse CD8a

  • PerCP/Cyanine5.5 anti-mouse CD8a

  • PerCP anti-mouse CD8a

  • Brilliant Violet 421™ anti-mouse CD8a

  • Brilliant Violet 570™ anti-mouse CD8a

  • Brilliant Violet 650™ anti-mouse CD8a

  • Brilliant Violet 605™ anti-mouse CD8a

  • Ultra-LEAF™ Purified anti-mouse CD8a

  • Brilliant Violet 711™ anti-mouse CD8a

  • Brilliant Violet 785™ anti-mouse CD8a

  • Brilliant Violet 510™ anti-mouse CD8a

  • Purified anti-mouse CD8a (Maxpar® Ready)

  • Alexa Fluor® 594 anti-mouse CD8a

  • PE/Dazzle™ 594 anti-mouse CD8a

  • APC/Fire™ 750 anti-mouse CD8a

  • GoInVivo™ Purified anti-mouse CD8a

  • TotalSeq™-A0002 anti-mouse CD8a

  • Spark Blue™ 550 anti-mouse CD8a

  • Spark NIR™ 685 anti-mouse CD8a

  • TotalSeq™-C0002 anti-mouse CD8a

  • TotalSeq™-B0002 anti-mouse CD8a

  • Spark YG™ 570 anti-mouse CD8a

  • PE/Fire™ 640 anti-mouse CD8a

  • PE/Fire™ 700 anti-mouse CD8a

  • Spark Blue™ 574 anti-mouse CD8a Antibody

  • Spark Violet™ 423 anti-mouse CD8a Antibody

  • Spark UV™ 387 anti-mouse CD8a

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account